CN108324913A - A kind of Chinese medicine composition that treating obesity and its application - Google Patents
A kind of Chinese medicine composition that treating obesity and its application Download PDFInfo
- Publication number
- CN108324913A CN108324913A CN201810357615.8A CN201810357615A CN108324913A CN 108324913 A CN108324913 A CN 108324913A CN 201810357615 A CN201810357615 A CN 201810357615A CN 108324913 A CN108324913 A CN 108324913A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- chinese
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition for treating obesity, the Chinese medicine composition is made of following bulk pharmaceutical chemicals:Talcum, Rhizoma Atractylodis Macrocephalae, campanulaceae, Chinese herbaceous peony, radix scutellariae, gypsum, Radix Glycyrrhizae, Radix Angelicae Sinensis, windproof, Chinese ephedra, Rhizoma Chuanxiong, cape jasmine, Fructus Forsythiae, schizonepeta, ginger, raw rhubarb, saltcake, Cortex Magnoliae Officinalis, the dried immature fruit of citron orange.The present invention also provides the applications of the Chinese medicine composition.Its advantage is shown:Each taste bulk pharmaceutical chemicals compatibility of Chinese medicine composition of the present invention is proper, under the comprehensive function of each taste bulk pharmaceutical chemicals, can effectively treat obesity, Obesity-type Polycystic Ovary Syndrome.The Chinese medicinal composition preparation curative effect of the present invention is excellent, and Small side effects can be used for a long time, and has wide clinical generalization value.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, specifically, being a kind of Chinese medicine composition that treating obesity and its application.
Background technology
Fat is at present fashion trend in the whole world, and obesity is both a kind of independent disease and diabetes B, painstaking effort
Pipe disease, the risk factor of hypertension, apoplexy and kinds cancer are classified as the ten big danger for leading to Disease Spectrum by the World Health Organization
One of factor.The current overweight person in China is up to 22.4%, and overweight people 3.01%, therefore prevents to have become with obesity controlling disease
Very urgent task.
The general characteristic of obesity patient is that the volume of body fat cell and cell number increase, the percentage of body fat percentage of liveweight
It is higher than abnormal, and excessively deposit fat in certain parts.If fat is mainly excessive in stomach wall and intraperitoneal accumulation, it is referred to as
" centre type " or " centrality " is fat, then very big to metabolic effect.
No endocrine system disease or can not find may cause fat specific disease because obesity be simple obesity.Pure
Overweight people accounts for 95% or more of fat total number of persons.The journey that the observation of human body appearance usually can substantially be estimated by obesity and become thin
Degree is suitable for primary dcreening operation, but without standard measure.Clinically with the most practical human body of in epidemiological survey, estimating obese degree
Surveying index is body mass index and waistline.
Chinese patent literature CN103223143A discloses a kind of Chinese medicine composition for treating simple obesity:Rhizoma Atractylodis Macrocephalae, toast
Turtle shell, Inula britannica chinensis, curcuma zedoary, giant knotweed.Chinese patent literature CN102370747A discloses a kind of herbal mixture system for treating obesity
Agent:Hawthorn, the tuber of multiflower knotweed, Radix Salviae Miltiorrhizae, pueraria lobata, Radix Astragali, Rhizoma Atractylodis Macrocephalae, Poria cocos, the tuber of pinellia, dried orange peel, rheum officinale, Radix Notoginseng.Chinese patent literature
CN104127514A discloses a kind of Chinese medicine compound prescription for treating obesity:Radix Astragali, rhizoma atractylodis, Cortex Magnoliae Officinalis and cimicifugae foetidae.Chinese patent literature
CN103417950A discloses a kind of Chinese medicine composition merging dyslipidemia for preventing obese type 2 diabetes mellitus:The coptis, hardship
Melon, rhizoma anemarrhenae, aloe, red yeast rice, Schisandra chinensis, rhizoma zingiberis and Radix Salviae Miltiorrhizae.But the Chinese medicine composition mesh of the treatment obesity about the present invention
Before have not been reported.
Invention content
First purpose of the present invention is, for deficiency in the prior art, to provide a kind of Chinese medicine group for treating obesity
Close object.
Second object of the present invention is to provide a kind of application of Chinese medicine composition.
To realize above-mentioned first purpose, the technical solution adopted by the present invention is that:A kind of Chinese traditional medicine composition for treating obesity
Object, the Chinese medicine composition are made of the bulk pharmaceutical chemicals of following parts by weight:4~8 parts of talcum, 3~5 parts of Rhizoma Atractylodis Macrocephalae, 3~5 parts of campanulaceae,
2~4 parts of Chinese herbaceous peony, 3~5 parts of radix scutellariae, 3~5 parts of gypsum, 3~5 parts of Radix Glycyrrhizae, 2~4 parts of Radix Angelicae Sinensis, 2~4 parts windproof, 2~4 parts of Chinese ephedra,
2~4 parts of Rhizoma Chuanxiong, 2~4 parts of cape jasmine, 2~4 parts of Fructus Forsythiae, 2~4 parts of schizonepeta, 0.7~1.3 part of ginger, 2~4 parts of raw rhubarb, saltcake 4
~8 parts, 10~20 parts of Cortex Magnoliae Officinalis, 10~20 parts of the dried immature fruit of citron orange.
Preferably, the Chinese medicine composition is made of the bulk pharmaceutical chemicals of following parts by weight:5~7 parts of talcum, Rhizoma Atractylodis Macrocephalae 3.5~
4.5 parts, 3.5~4.5 parts of campanulaceae, 2.5~3.5 parts of Chinese herbaceous peony, 3.5~4.5 parts of radix scutellariae, 3.5~4.5 parts of gypsum, Radix Glycyrrhizae 3.5~
4.5 parts, 2.5~3.5 parts of Radix Angelicae Sinensis, 2.5~3.5 parts windproof, 2.5~3.5 parts of Chinese ephedra, 2.5~3.5 parts of Rhizoma Chuanxiong, cape jasmine 2.5~
3.5 parts, 2.5~3.5 parts of Fructus Forsythiae, 2.5~3.5 parts of schizonepeta, 0.9~1.1 part of ginger, 2.5~3.5 parts of raw rhubarb, saltcake 5~7
Part, 13~17 parts of Cortex Magnoliae Officinalis, 13~17 parts of the dried immature fruit of citron orange.
Preferably, the Chinese medicine composition is made of the bulk pharmaceutical chemicals of following parts by weight:6 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, campanulaceae 4
Part, 4 parts of radix scutellariae, 4 parts of gypsum, 4 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, 3 parts windproof, 3 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, connects 3 parts of Chinese herbaceous peony
Stick up 3 parts, 3 parts of schizonepeta, 1 part of ginger, 3 parts of raw rhubarb, 6 parts of saltcake, 15 parts of Cortex Magnoliae Officinalis, 15 parts of the dried immature fruit of citron orange.
To realize above-mentioned second purpose, the technical solution adopted by the present invention is that:The Chinese medicine composition is controlled in preparation
Treat the application in the drug of obesity.
The pharmaceutical dosage form is oral preparation.
The oral preparation includes tablet, capsule, granule, oral solution, pill, syrup.
The obesity is simple obesity or secondary obesity.
Application of the Chinese medicine composition in the drug for preparing treatment Obesity-type Polycystic Ovary Syndrome.
The invention has the advantages that:
1, each taste bulk pharmaceutical chemicals compatibility of Chinese medicine composition of the invention is proper, under the comprehensive function of each taste bulk pharmaceutical chemicals, can have
Effect treatment obesity.
2, Chinese medicine composition of the invention can effectively treat Obesity-type Polycystic Ovary Syndrome.
3, Chinese medicinal composition preparation curative effect of the invention is excellent, and Small side effects can be used for a long time, and there is wide clinic to push away
Wide value.
Specific implementation mode
It elaborates to specific implementation mode provided by the invention with reference to embodiment.
1 Chinese medicine composition of embodiment
6 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, 4 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 4 parts of gypsum, 4 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, windproof 3
Part, 3 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 3 parts of Fructus Forsythiae, 3 parts of schizonepeta, 1 part of ginger, 3 parts of raw rhubarb, 6 parts of saltcake, Cortex Magnoliae Officinalis 15
Part, 15 parts of the dried immature fruit of citron orange.
2 Chinese medicine composition of embodiment
5 parts of talcum, 3.5 parts of Rhizoma Atractylodis Macrocephalae, 3.5 parts of campanulaceae, 2.5 parts of Chinese herbaceous peony, 3.5 parts of radix scutellariae, 3.5 parts of gypsum, 3.5 parts of Radix Glycyrrhizae,
2.5 parts of Radix Angelicae Sinensis, 2.5 parts windproof, 2.5 parts of Chinese ephedra, 2.5 parts of Rhizoma Chuanxiong, 2.5 parts of cape jasmine, 2.5 parts of Fructus Forsythiae, 2.5 parts of schizonepeta, ginger 0.9
Part, 2.5 parts of raw rhubarb, 5 parts of saltcake, 13 parts of Cortex Magnoliae Officinalis, 13 parts of the dried immature fruit of citron orange.
3 Chinese medicine composition of embodiment
5 parts of talcum, 4 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 3.5 parts of radix scutellariae, 4 parts of gypsum, 4 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, is prevented 4 parts of Rhizoma Atractylodis Macrocephalae
2.5 parts of wind, 3 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 2.5 parts of Fructus Forsythiae, 3 parts of schizonepeta, 1 part of ginger, 2.5 parts of raw rhubarb, saltcake 6
Part, 15 parts of Cortex Magnoliae Officinalis, 15 parts of the dried immature fruit of citron orange.
4 Chinese medicine composition of embodiment
5 parts of talcum, 4.5 parts of Rhizoma Atractylodis Macrocephalae, 4.5 parts of campanulaceae, 3.5 parts of Chinese herbaceous peony, 3.5 parts of radix scutellariae, 4.5 parts of gypsum, 4.5 parts of Radix Glycyrrhizae,
3.5 parts of Radix Angelicae Sinensis, 2.5 parts windproof, 3.5 parts of Chinese ephedra, 3.5 parts of Rhizoma Chuanxiong, 3.5 parts of cape jasmine, 2.5 parts of Fructus Forsythiae, 3.5 parts of schizonepeta, ginger 1.1
Part, 2.5 parts of raw rhubarb, 7 parts of saltcake, 17 parts of Cortex Magnoliae Officinalis, 17 parts of the dried immature fruit of citron orange.
5 Chinese medicine composition of embodiment
6 parts of talcum, 3.5 parts of Rhizoma Atractylodis Macrocephalae, 4 parts of campanulaceae, 3.5 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 3.5 parts of gypsum, 4 parts of Radix Glycyrrhizae, Radix Angelicae Sinensis 3.5
Part, 3 parts windproof, 2.5 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 3.5 parts of cape jasmine, 3 parts of Fructus Forsythiae, 3 parts of schizonepeta, 1.1 parts of ginger, 3 parts of raw rhubarb, awns
5 parts of nitre, 15 parts of Cortex Magnoliae Officinalis, 17 parts of the dried immature fruit of citron orange.
6 Chinese medicine composition of embodiment
6 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, 4.5 parts of campanulaceae, 2.5 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 4 parts of gypsum, 4.5 parts of Radix Glycyrrhizae, Radix Angelicae Sinensis 2.5
Part, 3 parts windproof, 3 parts of Chinese ephedra, 3.5 parts of Rhizoma Chuanxiong, 2.5 parts of cape jasmine, 3 parts of Fructus Forsythiae, 3.5 parts of schizonepeta, 0.9 part of ginger, 3 parts of raw rhubarb,
6 parts of saltcake, 17 parts of Cortex Magnoliae Officinalis, 13 parts of the dried immature fruit of citron orange.
7 Chinese medicine composition of embodiment
6 parts of talcum, 4.5 parts of Rhizoma Atractylodis Macrocephalae, 3.5 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 4.5 parts of gypsum, 3.5 parts of Radix Glycyrrhizae, Radix Angelicae Sinensis 3
Part, 3 parts windproof, 3.5 parts of Chinese ephedra, 2.5 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 3 parts of Fructus Forsythiae, 2.5 parts of schizonepeta, 1 part of ginger, 3 parts of raw rhubarb, awns
7 parts of nitre, 13 parts of Cortex Magnoliae Officinalis, 15 parts of the dried immature fruit of citron orange.
8 Chinese medicine composition of embodiment
7 parts of talcum, 3.5 parts of Rhizoma Atractylodis Macrocephalae, 4.5 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 4.5 parts of radix scutellariae, 3.5 parts of gypsum, 4.5 parts of Radix Glycyrrhizae, when
Return 3 parts, 3.5 parts windproof, 2.5 parts of Chinese ephedra, 3.5 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 3.5 parts of Fructus Forsythiae, 3.5 parts of schizonepeta, 1 part of ginger, give birth to greatly
3.5 parts yellow, 5 parts of saltcake, 17 parts of Cortex Magnoliae Officinalis, 15 parts of the dried immature fruit of citron orange.
9 Chinese medicine composition of embodiment
7 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, 3.5 parts of campanulaceae, 3.5 parts of Chinese herbaceous peony, 4.5 parts of radix scutellariae, 4 parts of gypsum, 3.5 parts of Radix Glycyrrhizae, Radix Angelicae Sinensis
3.5 parts, it is 3.5 parts windproof, 3 parts of Chinese ephedra, 2.5 parts of Rhizoma Chuanxiong, 3.5 parts of cape jasmine, 3.5 parts of Fructus Forsythiae, 2.5 parts of schizonepeta, 1.1 parts of ginger, raw
3.5 parts of rheum officinale, 6 parts of saltcake, 13 parts of Cortex Magnoliae Officinalis, 17 parts of the dried immature fruit of citron orange.
10 Chinese medicine composition of embodiment
7 parts of talcum, 4.5 parts of Rhizoma Atractylodis Macrocephalae, 4 parts of campanulaceae, 2.5 parts of Chinese herbaceous peony, 4.5 parts of radix scutellariae, 4.5 parts of gypsum, 4 parts of Radix Glycyrrhizae, Radix Angelicae Sinensis
2.5 parts, it is 3.5 parts windproof, 3.5 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 2.5 parts of cape jasmine, 3.5 parts of Fructus Forsythiae, 3 parts of schizonepeta, 0.9 part of ginger, raw big
3.5 parts yellow, 7 parts of saltcake, 15 parts of Cortex Magnoliae Officinalis, 13 parts of the dried immature fruit of citron orange.
11 Chinese medicine composition of embodiment
4 parts of talcum, 3 parts of Rhizoma Atractylodis Macrocephalae, 3 parts of campanulaceae, 2 parts of Chinese herbaceous peony, 3 parts of radix scutellariae, 3 parts of gypsum, 3 parts of Radix Glycyrrhizae, 2 parts of Radix Angelicae Sinensis, windproof 2
Part, 2 parts of Chinese ephedra, 2 parts of Rhizoma Chuanxiong, 2 parts of cape jasmine, 2 parts of Fructus Forsythiae, 2 parts of schizonepeta, 0.7 part of ginger, 2 parts of raw rhubarb, 4 parts of saltcake, Cortex Magnoliae Officinalis 10
Part, 10 parts of the dried immature fruit of citron orange.
12 Chinese medicine composition of embodiment
4 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, 4 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 3 parts of radix scutellariae, 4 parts of gypsum, 4 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, windproof 2
Part, 3 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 2 parts of Fructus Forsythiae, 3 parts of schizonepeta, 1 part of ginger, 2 parts of raw rhubarb, 6 parts of saltcake, Cortex Magnoliae Officinalis 15
Part, 15 parts of the dried immature fruit of citron orange.
13 Chinese medicine composition of embodiment
4 parts of talcum, 5 parts of Rhizoma Atractylodis Macrocephalae, 5 parts of campanulaceae, 4 parts of Chinese herbaceous peony, 3 parts of radix scutellariae, 5 parts of gypsum, 5 parts of Radix Glycyrrhizae, 4 parts of Radix Angelicae Sinensis, windproof 2
Part, 4 parts of Chinese ephedra, 4 parts of Rhizoma Chuanxiong, 4 parts of cape jasmine, 2 parts of Fructus Forsythiae, 4 parts of schizonepeta, 1.3 parts of ginger, 2 parts of raw rhubarb, 8 parts of saltcake, Cortex Magnoliae Officinalis 20
Part, 20 parts of the dried immature fruit of citron orange.
14 Chinese medicine composition of embodiment
6 parts of talcum, 3 parts of Rhizoma Atractylodis Macrocephalae, 4 parts of campanulaceae, 4 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 3 parts of gypsum, 4 parts of Radix Glycyrrhizae, 4 parts of Radix Angelicae Sinensis, windproof 3
Part, 2 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 4 parts of cape jasmine, 3 parts of Fructus Forsythiae, 3 parts of schizonepeta, 1.3 parts of ginger, 3 parts of raw rhubarb, 4 parts of saltcake, Cortex Magnoliae Officinalis 15
Part, 20 parts of the dried immature fruit of citron orange.
15 Chinese medicine composition of embodiment
6 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, 5 parts of campanulaceae, 2 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 4 parts of gypsum, 5 parts of Radix Glycyrrhizae, 2 parts of Radix Angelicae Sinensis, windproof 3
Part, 3 parts of Chinese ephedra, 4 parts of Rhizoma Chuanxiong, 2 parts of cape jasmine, 3 parts of Fructus Forsythiae, 4 parts of schizonepeta, 0.7 part of ginger, 3 parts of raw rhubarb, 6 parts of saltcake, Cortex Magnoliae Officinalis 20
Part, 10 parts of the dried immature fruit of citron orange.
16 Chinese medicine composition of embodiment
6 parts of talcum, 5 parts of Rhizoma Atractylodis Macrocephalae, 3 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 5 parts of gypsum, 3 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, windproof 3
Part, 4 parts of Chinese ephedra, 2 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 3 parts of Fructus Forsythiae, 2 parts of schizonepeta, 1 part of ginger, 3 parts of raw rhubarb, 8 parts of saltcake, Cortex Magnoliae Officinalis 10
Part, 15 parts of the dried immature fruit of citron orange.
17 Chinese medicine composition of embodiment
8 parts of talcum, 3 parts of Rhizoma Atractylodis Macrocephalae, 5 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 5 parts of radix scutellariae, 3 parts of gypsum, 5 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, windproof 4
Part, 2 parts of Chinese ephedra, 4 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 4 parts of Fructus Forsythiae, 4 parts of schizonepeta, 1 part of ginger, 4 parts of raw rhubarb, 4 parts of saltcake, Cortex Magnoliae Officinalis 20
Part, 15 parts of the dried immature fruit of citron orange.
18 Chinese medicine composition of embodiment
8 parts of talcum, 4 parts of Rhizoma Atractylodis Macrocephalae, 3 parts of campanulaceae, 4 parts of Chinese herbaceous peony, 5 parts of radix scutellariae, 4 parts of gypsum, 3 parts of Radix Glycyrrhizae, 4 parts of Radix Angelicae Sinensis, windproof 4
Part, 3 parts of Chinese ephedra, 2 parts of Rhizoma Chuanxiong, 4 parts of cape jasmine, 4 parts of Fructus Forsythiae, 2 parts of schizonepeta, 1.3 parts of ginger, 4 parts of raw rhubarb, 6 parts of saltcake, Cortex Magnoliae Officinalis 10
Part, 20 parts of the dried immature fruit of citron orange.
19 Chinese medicine composition of embodiment
8 parts of talcum, 5 parts of Rhizoma Atractylodis Macrocephalae, 4 parts of campanulaceae, 2 parts of Chinese herbaceous peony, 5 parts of radix scutellariae, 5 parts of gypsum, 4 parts of Radix Glycyrrhizae, 2 parts of Radix Angelicae Sinensis, windproof 4
Part, 4 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 2 parts of cape jasmine, 4 parts of Fructus Forsythiae, 3 parts of schizonepeta, 0.7 part of ginger, 4 parts of raw rhubarb, 8 parts of saltcake, Cortex Magnoliae Officinalis 15
Part, 10 parts of the dried immature fruit of citron orange.
20 tablet of embodiment
Medicinal material is cleaned, is mixed, 4 times of water of dosing material total weight decocts 3 times, 50 minutes every time, merges 3 decoctions
Liquid, filtering, and concentrate, obtain the liquid extract that proportion is 1.10 at 60 DEG C.
By liquid extract according to the operating method of conventional tablet, pharmaceutic adjuvant is added, each component is uniformly mixed, wet method system
Grain, sieving, tablet is made using conventional tablet the preparation method tabletting.The dosage of each component is:It is 50 parts of liquid extract, 25 parts of starch, micro-
12 parts of crystalline cellulose, 12 parts of talcum powder, 8 parts of polyethylene glycol.
21 capsule of embodiment
Medicinal material is cleaned, is mixed, 5 times of water of dosing material total weight decocts 3 times, 50 minutes every time, merges 3 decoctions
Liquid, filtering, and concentrate, obtain the liquid extract that proportion is 1.10 at 60 DEG C.
According to the operating method of conventional capsule, pharmaceutic adjuvant is added, each component is uniformly mixed, pelletizes, using routine
Capsule is made in the filling of capsule the preparation method.The dosage of each component is:100 parts of liquid extract, 32 parts of pre-gelatinized starch, Lactis Anhydrous
18 parts, 15 parts of microcrystalline cellulose, 8 parts of calcium monohydrogen phosphate.
22 oral solution of embodiment
Medicinal material is cleaned, is mixed, 6 times of water of dosing material total weight decocts 3 times, 50 minutes every time, merges 3 decoctions
Liquid, filtering, and concentrate, obtain the liquid extract that proportion is 1.10 at 60 DEG C.
According to the operating method of traditional oral liquid, ethanol precipitation 1~2 time filters, concentration, and aqueous precipitation filters, and is added
Pharmaceutic adjuvant, filtering, packing sterilizing.The dosage of each component is:100 parts of liquid extract, 160 parts of ethyl alcohol, 75 parts of sucrose, carboxymethyl are fine
Plain 13 parts of the sodium of dimension, 6 parts of peppermint oil, 3 parts of sorbic acid.
23 water decoction of embodiment
Medicinal material is cleaned, mixes, adds water to cook to obtain water decoction.
24 animal experiment of embodiment
1, experimental animal
Wistar rats, 200 ± 20g of weight, male.100 Wistar rats are randomly divided into 10 groups, every group each 10.
2, experimental method
Normal group:Feeding normal diet
Remaining each group:Feeding high lipid food
The preparation of high lipid food:Add 2% cholesterol, 10% lard, 0.2% methylthiouracil in basal feed.
3, medication
A groups:Normal group, daily gavage physiological saline, 20ml/kg, one time a day, successive administration 14 days.
B groups:Modeling group, daily gavage physiological saline, 20ml/kg, one time a day, successive administration 14 days.
C groups:Fangfeng tongsheng pill (2.5g/kgd) is configured to suspension oral gavage with carboxymethyl cellulose, 20ml/kg, often
Day 1 time, successive administration 14 days.
D groups:Fenofibrate (0.3g/kgd) is configured to suspension oral gavage with carboxymethyl cellulose, 20ml/kg, and daily 1
It is secondary, successive administration 14 days.
E groups:1 part of ginger, 15 parts of Cortex Magnoliae Officinalis, 15 parts of the dried immature fruit of citron orange, are made water decoction, are equivalent to crude drug amount 2.5g/kgd, decocting
Agent 20ml/kg gavages, one time a day, successive administration 14 days.
F groups:The Chinese medicine composition of embodiment 1, is made water decoction, is equivalent to crude drug amount 5.0g/kgd, water decoction 20ml/
Kg gavages, one time a day, successive administration 14 days.
G groups:The Chinese medicine composition of embodiment 1, is made water decoction, is equivalent to crude drug amount 2.5g/kgd, water decoction 20ml/
Kg gavages, one time a day, successive administration 14 days.
H groups:The Chinese medicine composition of embodiment 1, is made water decoction, is equivalent to crude drug amount 1.25g/kgd, water decoction
20ml/kg gavages, one time a day, successive administration 14 days.
I groups:The Chinese medicine composition of embodiment 8, is made water decoction, is equivalent to crude drug amount 2.5g/kgd, water decoction 20ml/
Kg gavages, one time a day, successive administration 14 days.
J groups:The Chinese medicine composition of embodiment 15, is made water decoction, is equivalent to crude drug amount 2.5g/kgd, water decoction
20ml/kg gavages, one time a day, successive administration 14 days.
4, detection method
Fasting (can't help water) 14 hours after the last administration, weigh, and etherization, abdominal vein takes blood, centrifugation,
3000rpm 15 minutes, prepares serum, as detection sample.Total cholesterol TC uses CHOD-PAP methods, triglycerides TG to use
GPO-PAP methods, high-density lipoprotein HDL-C use PTA-Mg2+Method, low-density lipoprotein LDL-C use PVS methods, concrete operations
It is carried out by test kits specification requirement.
5, result
Testing result is as shown in 1~table of table 4.
Table 1
Table 2
Table 3
Table 4
25 clinical test of embodiment
1, general information
Obese patient 80, man 36, female 44;It is 20~62 years old age, 30 years old average.80 patients are randomly divided into 2
Group, treatment group and each 40 of control group.
2, diagnostic criteria
(1) waistline >=80cm;
(2) waist-to-hipratio (WHR) >=0.85;
(3) body mass index (BMI) man >=27, female >=25.
It is all to meet above 2 standard persons and be included in observation.
3, observation index and method
Patient erect measures
(1) abdominal circumference (MC) on:1 week length (cm) is surround through xiphoid-process and navel line midpoint (ZHONGWAN acupoint);
(2) waistline (WC):1 week length (cm) is surround through Qizhong;
(3) abdominal circumference (HMC) under:1 week length (cm) is surround through midpoint between Qizhong and upper margin of pubic bone;
(4) hip circumference (HC):1 week length (cm) is surround through buttocks femoral bone tuberosity;
(5) WHR=WC/HC;
(6) BMI=weights (kg)/(height (m))2。
4, therapy
Treatment group:The medicinal material of embodiment 1 is cleaned, is mixed, 5 times of water of dosing material total weight decocts 3 times, every time 50 points
Clock merges 3 decoction liquors, filtering, and concentrates, and obtains the liquid extract that proportion is 1.10 at 60 DEG C.Chinese medical concrete obtained is pressed
Volume with water dilutes 10 times, is taken to patient, everyone takes orally 100ml every time, twice a day.
Control group:1 80mg of oral hydrochloride diethylpropion takes for 1.5~2 hours before meals 2 times a day.
The course for the treatment of of treatment group and control group is 2 months.
5, result
The result of variations of each observation index is as shown in the table after treatment.
The variation of each observation index after table 5 is treated
From efficacy experiment as can be seen that the curative effect of the present invention Western medicine with obvious effects higher than treatment obesity, nothing are apparent not
Good reaction.
26 clinical test of embodiment
1, general information
40 cases, which derive from our hospital's outpatient service and are hospitalized, is diagnosed as metabolic abnormalities of obese women with obese polycystic ovary syndrome.It is randomly divided into
Two groups, treatment group and each 20 of control group are statistically analyzed, two group differences are without conspicuousness (P > 0.05).
2, inclusion criteria
Meet the diagnostic criteria of Stein-Leventhal syndrome and obesity simultaneously.
The diagnostic criteria of Stein-Leventhal syndrome:
(1) a small number of or No-clay weak interbed,
(2) clinical and/or biochemistry has the performance of excessive androgen,
(3) ultrasonic examination find polycystic ovary and exclude other diseases (such as congenital adrenal hyperplasia, Cushing syndrome and
Androgen secretion tumour etc.).
Obesity classification:
With BMI values 23 for overweight boundary, normal (BMI18.5~22.9), fat early period (BMI23~24.9), I degree fertilizer
Fat (BMI25~29.9), II degree are fat (BMI >=30).
The treatment for not receiving that reproductive hormone and glycometabolism may be influenced in nearly 3 months.Hepatic and renal function is normal, excludes thyroid gland kidney
Other endocrine disorders such as upper gland.
Exclusion criteria:
(1) sex hormone drug was used in nearly March, or participates in the patient of other clinical tests;
(2) primary diseases such as liver kidney, cardiovascular and cerebrovascular and hematopoietic disorder are associated with;
(3) mental patient.
3, detection method
3.1, endocrine hormone measures
Two groups in the 3rd~5 day menstrual cycle or the amenorrhoea person morning 8 when ultrasound diagnosis has no dominant follicle:00~9:00
Ulnar vein blood sampling 5ml, cryogenic separation serum, low temperature refrigerator storage are to be measured on an empty stomach.Serum follicle-stimulating hormone (FSH) is measured with radioimmunoassay
(FSH), interstitialcellstimulating hormone (ICSH) (LH), total testosterone (T), insulin-like growth factor (IGF-1).
3.2 ultrasonic examination
Uterus and bilateral ovaries are detected, its long and short radial line is measured when eliciting maximum ovary section, calculate cubature formula:π/6
× major diameter × minor axis2。
4, therapy
Treatment group:The Chinese medicine composition of embodiment 1.
Control group:The Miraculous Power of Ledebouriella.
Water decoction, day is one, and morning and afternoon is divided to take, and March is as a treatment course.Menstrual period withdraw.
5, curative effect index
(1) menstruation;
(2) fat situation;
(3) tcm syndrome and tongue vein variation;
(4) FSH, LH, T change;
(5) IGF-1 changes;
(6) basal body temperature changes;
(7) B ultrasound changes;
(8) body mass index changes.
All patients check reproductive hormone, blood biochemistry and B ultrasound after 1 course for the treatment of.
6, efficacy determination
6.1, clinical efficacy judges
It is issued with reference to health ministry《New Chinese medicine guideline of clinical investigations》It formulates:
It cures:Menstruation recovery normal cycle and ovulation restore normal, and physiological hormone T values and corresponding symptom are normal, and B ultrasound is just
Often.
Effectively:Menstrual onset but irregular, ovulation does not restore, and physiological hormone T values and corresponding symptom are obviously improved, companion or not
It has clear improvement with LH/FSH, ultrasound diagnosis has improvement.
In vain:Through continuously treating 3 periods, menstruation, which has no, rises, and physiological hormone T values are horizontal and other symptoms are without obviously changing
Kind, ultrasound diagnosis is not improved.
6.2, tcm syndrome curative effect determinate standard
Total mark × 100% before therapeutic effect of syndrome rate=(total mark after total mark-treatment before treatment)/treatment
Recovery from illness:Therapeutic effect of syndrome rate >=90% after treatment
It is effective:Therapeutic effect of syndrome rate < 90% after 70%≤treatment
Effectively:Therapeutic effect of syndrome rate < 70% after 30%≤treatment
In vain:Therapeutic effect of syndrome rate < 30% after treatment
Clinical manifestation and Chinese medicine syndrome integral according to《Chinese medicine Quantitative Diagnosis》It drafts.
6.3, BMI curative effect judging standards
Recovery from illness:Constitutional index reduces by 3 indexes or more or weight is down to normally;
It is effective:Constitutional index reduces by 0.5~3 index;
In vain:Constitutional index is less than 0.5 index, and weight does not change before and after treatment.
6.4, ultrasonic examination efficacy determination
Recovery from illness:B ultrasound is shown in that bilateral ovaries become or increase Ovarian Volume without more capsule samples and reduce 45% or more;
It is effective:B ultrasound is shown in bilateral ovaries volume-diminished 30%~45%;
Effectively:B ultrasound is shown in bilateral ovaries volume-diminished 15%~30%;
In vain:B ultrasound is shown in before bilateral ovaries relatively treatment is less than 15% without change or volume-diminished.
7, result
7.1 comprehensive therapeutic effect
Comprehensive therapeutic effect the results are shown in Table 6, and for the total effective rate for the treatment of group up to 90%, treatment group is significant in efficacy to be better than control group (P <
0.05)。
6 two groups of Clinical efficacy comparisons of table
7.2, clinical manifestation and tcm syndrome curative effect
Clinical manifestation is shown in Table 7 with tcm syndrome efficacy result, treats preceding two groups of tcm syndrome total marks and compares without apparent poor
Different, treatment group is significantly better than control group (P < 0.05) in terms of mitigating symptom.
7 two groups of tcm syndrome total marks of table compare
7.3, pretherapy and post-treatment basal body temperature
Pretherapy and post-treatment basal body temperature the results are shown in Table 8.
8 pretherapy and post-treatment basal body temperature of table changes
7.4, pretherapy and post-treatment obesity index
Pretherapy and post-treatment obesity index the results are shown in Table 9.Not statistically significant difference between first two groups for the treatment of, after treatment, treatment group
Decline degree is significantly better than control group (P < 0.05).
Table 9 pretherapy and post-treatment BMI variations
7.5, pretherapy and post-treatment sex hormone level compares
Pretherapy and post-treatment sex hormone level comparison result see the table below shown.
10 pretherapy and post-treatment T of table compares
11 pretherapy and post-treatment LH of table compares
12 pretherapy and post-treatment FSH of table compares
7.6, pretherapy and post-treatment IGF-1 compares
Pretherapy and post-treatment IGF-1 comparison results are shown in Table 13.
13 pretherapy and post-treatment IGF-1 of table compares
7.7, pretherapy and post-treatment B ultrasound compares
Pretherapy and post-treatment B ultrasound comparison result is shown in Table 14.
14 pretherapy and post-treatment B ultrasound of table compares
Safety detection
Two groups of patients are without obvious adverse reaction.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, under the premise of not departing from the method for the present invention, can also make several improvement and supplement, these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (8)
1. a kind of Chinese medicine composition for treating obesity, which is characterized in that the Chinese medicine composition by following parts by weight original
Material medicine is made:It is 4~8 parts of talcum, 3~5 parts of Rhizoma Atractylodis Macrocephalae, 3~5 parts of campanulaceae, 2~4 parts of Chinese herbaceous peony, 3~5 parts of radix scutellariae, 3~5 parts of gypsum, sweet
3~5 parts of grass, 2~4 parts of Radix Angelicae Sinensis, 2~4 parts windproof, 2~4 parts of Chinese ephedra, 2~4 parts of Rhizoma Chuanxiong, 2~4 parts of cape jasmine, 2~4 parts of Fructus Forsythiae, chaste tree
2~4 parts of mustard, 0.7~1.3 part of ginger, 2~4 parts of raw rhubarb, 4~8 parts of saltcake, 10~20 parts of Cortex Magnoliae Officinalis, 10~20 parts of the dried immature fruit of citron orange.
2. Chinese medicine composition according to claim 1, which is characterized in that the Chinese medicine composition is by following parts by weight
Bulk pharmaceutical chemicals are made:5~7 parts of talcum, 3.5~4.5 parts of Rhizoma Atractylodis Macrocephalae, 3.5~4.5 parts of campanulaceae, 2.5~3.5 parts of Chinese herbaceous peony, radix scutellariae 3.5~
4.5 parts, 3.5~4.5 parts of gypsum, 3.5~4.5 parts of Radix Glycyrrhizae, 2.5~3.5 parts of Radix Angelicae Sinensis, 2.5~3.5 parts windproof, Chinese ephedra 2.5~
3.5 parts, 2.5~3.5 parts of Rhizoma Chuanxiong, 2.5~3.5 parts of cape jasmine, 2.5~3.5 parts of Fructus Forsythiae, 2.5~3.5 parts of schizonepeta, ginger 0.9~
1.1 parts, 2.5~3.5 parts of raw rhubarb, 5~7 parts of saltcake, 13~17 parts of Cortex Magnoliae Officinalis, 13~17 parts of the dried immature fruit of citron orange.
3. Chinese medicine composition according to claim 1, which is characterized in that the Chinese medicine composition is by following parts by weight
Bulk pharmaceutical chemicals are made:6 parts of talcum, 4 parts of campanulaceae, 3 parts of Chinese herbaceous peony, 4 parts of radix scutellariae, 4 parts of gypsum, 4 parts of Radix Glycyrrhizae, 3 parts of Radix Angelicae Sinensis, is prevented 4 parts of Rhizoma Atractylodis Macrocephalae
3 parts of wind, 3 parts of Chinese ephedra, 3 parts of Rhizoma Chuanxiong, 3 parts of cape jasmine, 3 parts of Fructus Forsythiae, 3 parts of schizonepeta, 1 part of ginger, 3 parts of raw rhubarb, 6 parts of saltcake, Cortex Magnoliae Officinalis
15 parts, 15 parts of the dried immature fruit of citron orange.
4. according to application of any Chinese medicine compositions of claim 1-3 in the drug for preparing treatment obesity.
5. application according to claim 4, which is characterized in that the pharmaceutical dosage form is oral preparation.
6. application according to claim 5, which is characterized in that the oral preparation includes tablet, capsule, particle
Agent, oral solution, pill, syrup.
7. application according to claim 4, which is characterized in that the obesity is simple obesity or secondary fertilizer
Fat disease.
8. according to any Chinese medicine compositions of claim 1-3 in the drug for preparing treatment Obesity-type Polycystic Ovary Syndrome
In application.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810357615.8A CN108324913B (en) | 2018-04-20 | 2018-04-20 | Traditional Chinese medicine composition for treating obesity and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810357615.8A CN108324913B (en) | 2018-04-20 | 2018-04-20 | Traditional Chinese medicine composition for treating obesity and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108324913A true CN108324913A (en) | 2018-07-27 |
CN108324913B CN108324913B (en) | 2020-09-29 |
Family
ID=62934306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810357615.8A Active CN108324913B (en) | 2018-04-20 | 2018-04-20 | Traditional Chinese medicine composition for treating obesity and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108324913B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111053838A (en) * | 2020-01-20 | 2020-04-24 | 辽宁百生医药有限公司 | Compound traditional Chinese medicine capable of physiologically curing obesity of boys and children |
CN114903939A (en) * | 2021-02-09 | 2022-08-16 | 鲁南制药集团股份有限公司 | New medical application of Jingfang preparation |
CN115252713A (en) * | 2022-08-23 | 2022-11-01 | 南昌市博泽康医药科技有限公司 | Traditional Chinese medicine composition for treating obesity and application thereof |
CN116236526A (en) * | 2023-02-07 | 2023-06-09 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879789A (en) * | 2006-05-17 | 2006-12-20 | 周国生 | A Chinese medicinal composition for treating blood heat type obesity |
-
2018
- 2018-04-20 CN CN201810357615.8A patent/CN108324913B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879789A (en) * | 2006-05-17 | 2006-12-20 | 周国生 | A Chinese medicinal composition for treating blood heat type obesity |
Non-Patent Citations (3)
Title |
---|
平野茂 等: ""防风通圣散的予防和治疗作用", 《成都中医学院学报》 * |
杨林芝 等: "减肥干预与肥胖型多囊卵巢综合征", 《哈尔滨多囊卵巢综合征国际论坛论文集》 * |
胡小勤 等: "《中药学》", 31 December 2013, 西安交通大学出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111053838A (en) * | 2020-01-20 | 2020-04-24 | 辽宁百生医药有限公司 | Compound traditional Chinese medicine capable of physiologically curing obesity of boys and children |
CN114903939A (en) * | 2021-02-09 | 2022-08-16 | 鲁南制药集团股份有限公司 | New medical application of Jingfang preparation |
CN114903939B (en) * | 2021-02-09 | 2023-05-16 | 鲁南制药集团股份有限公司 | New medical application of Jingfeng preparation |
CN115252713A (en) * | 2022-08-23 | 2022-11-01 | 南昌市博泽康医药科技有限公司 | Traditional Chinese medicine composition for treating obesity and application thereof |
CN115252713B (en) * | 2022-08-23 | 2023-04-28 | 南昌市博泽康医药科技有限公司 | Traditional Chinese medicine composition for treating obesity and application thereof |
CN116236526A (en) * | 2023-02-07 | 2023-06-09 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof |
CN116236526B (en) * | 2023-02-07 | 2024-02-06 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108324913B (en) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108324913A (en) | A kind of Chinese medicine composition that treating obesity and its application | |
CN105687994B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic renal failure | |
WO2021120972A1 (en) | Traditional chinese medicine composition for treating deficiency of both qi and blood, preparation method therefor and use thereof | |
CN101940716A (en) | Medicament for treating diabetic nephropathy | |
CN102671137A (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
CN102488743B (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
CN100418562C (en) | Medicinal composition, its preparing method and quality controlling means | |
CN101406598B (en) | Chinese medicine composite for treating diabetes and preparation method thereof | |
CN102370727A (en) | Compound Chinese medicinal preparation for treating depression and preparation method thereof | |
CN102091306A (en) | Medicine for treating senile chronic colitis | |
CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
CN108379365B (en) | Medicine for preventing and treating diarrhea-predominant irritable bowel syndrome and preparation method and application thereof | |
CN102370798A (en) | Chinese medicinal compound preparation for treating IgA (Immunoglobulin A) nephropathy and preparation method thereof | |
CN102293923A (en) | Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis | |
CN112933201A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof | |
CN102078571B (en) | Drug for treating early cirrhosis ascites | |
CN104491416B (en) | A kind of Chinese medicine composition for being used to treat diabetes | |
CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
CN116036162B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof | |
CN115645493B (en) | Traditional Chinese medicine preparation for treating chronic kidney disease stage 3 and preparation method thereof | |
CN108210873B (en) | Traditional Chinese medicine composition for increasing estrogen and application thereof | |
CN107469014A (en) | A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof | |
CN101628102A (en) | Medicament for preventing and treating fatty liver and preparation process thereof | |
CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
CN106177622A (en) | A kind of Chinese medicine composition treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |